DNA Methyltransferase Inhibitor Suppresses Corneal Scarring

Corneal fibrosis and opacity are major causes of visual impairment and blindness, while the conventional treatment by corneal transplantation remains limited due to the global shortage of donor materials and the risk of immune-mediated graft rejection. In this study, we investigated DNA methyltransferase (DNMT) inhibition using the FDA-approved agent decitabine (DAC; 5-aza-2′-deoxycytidine) to suppress corneal fibrosis. DNMT3A is a predicted target of the anti-fibrotic microRNA miR-29a, which was previously linked to the scar-reducing effects of cornealstromal stem cell-derived extracellular vesicles (doi:10.1016/j.jare.2022.05.008). DNMT3A expression was upregulated in scarred mouse corneas. In donor-derived corneal stromal fibroblasts, DAC dose-dependently suppressed TGFβ1-induced αSMA expression and attenuated myofibroblast-associated morphological and functional changes, including collagen gel contraction, at concentrations up to 50 μM. RNA sequencing further showed that DAC reversed TGFβ1-driven extracellular matrix remodeling, including changes in SPOCK1 and CTHRC1 expression. These effects were supported in injured mouse corneas, where topical DAC treatment reduced SPOCK1 and CTHRC1 expression, decreased scar formation, and restored corneal thickness toward normal levels. Fibrosis- and inflammation-associated gene expression was also downregulated, with no apparent treatment-related toxicity. In conclusion, these findings demonstrate that DNMT inhibition suppresses corneal fibrosis and myofibroblast differentiation, supporting the repurposing of DAC as a pharmacological, donor-independent strategy for reducing corneal fibrosis and preserving corneal transparency.

Authors

Institutions

Publication Details

Journal
Cells
Published
2026-11-13
DOI
https://doi.org/10.3390/cells15222071
Primary Topic
Corneal Surgery and Treatments
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

DNA Methyltransferase Inhibitor Suppresses Corneal Scarring

Deepinder K. Dhaliwal, Kun‐Che Chang, Gary Hin‐Fai Yam, Moira L. Geary et al.
2 links
Cells
Corneal Surgery and Treatments
article

DNA Methyltransferase Inhibitor Suppresses Corneal Scarring

Deepinder K. Dhaliwal, Kun‐Che Chang, Gary Hin‐Fai Yam, Moira L. Geary, Mithun Santra, Chi‐Yu Chen, Syeda R. Ali, Julia T Coelho, Vishal Jhanji, Ella J. Dewald
article en

Abstract

Corneal fibrosis and opacity are major causes of visual impairment and blindness, while the conventional treatment by corneal transplantation remains limited due to the global shortage of donor materials and the risk of immune-mediated graft rejection. In this study, we investigated DNA methyltransferase (DNMT) inhibition using the FDA-approved agent decitabine (DAC; 5-aza-2′-deoxycytidine) to suppress corneal fibrosis. DNMT3A is a predicted target of the anti-fibrotic microRNA miR-29a, which was previously linked to the scar-reducing effects of cornealstromal stem cell-derived extracellular vesicles (doi:10.1016/j.jare.2022.05.008). DNMT3A expression was upregulated in scarred mouse corneas. In donor-derived corneal stromal fibroblasts, DAC dose-dependently suppressed TGFβ1-induced αSMA expression and attenuated myofibroblast-associated morphological and functional changes, including collagen gel contraction, at concentrations up to 50 μM. RNA sequencing further showed that DAC reversed TGFβ1-driven extracellular matrix remodeling, including changes in SPOCK1 and CTHRC1 expression. These effects were supported in injured mouse corneas, where topical DAC treatment reduced SPOCK1 and CTHRC1 expression, decreased scar formation, and restored corneal thickness toward normal levels. Fibrosis- and inflammation-associated gene expression was also downregulated, with no apparent treatment-related toxicity. In conclusion, these findings demonstrate that DNMT inhibition suppresses corneal fibrosis and myofibroblast differentiation, supporting the repurposing of DAC as a pharmacological, donor-independent strategy for reducing corneal fibrosis and preserving corneal transparency.

CellsVol. 15(22)
University of Pittsburgh (US), McGowan Institute for Regenerative Medicine (US)
Eye and Ear Foundation of Pittsburgh, Hillman Foundation
Good health and well-being
Corneal Surgery and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon